X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (772) 772
Publication (71) 71
Book Review (9) 9
Magazine Article (8) 8
Book Chapter (3) 3
Book / eBook (2) 2
Web Resource (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (398) 398
index medicus (383) 383
animals (269) 269
thiazoles - therapeutic use (223) 223
thiazoles (184) 184
female (149) 149
male (148) 148
neonicotinoids (107) 107
food science & technology (103) 103
thiazoles - pharmacology (100) 100
thiazoles - economics (97) 97
toxicology (94) 94
pharmacology & pharmacy (91) 91
thiazoles - chemistry (89) 89
tetrazolium salts (81) 81
analysis (79) 79
thiamethoxam (79) 79
thiazoles - adverse effects (76) 76
insecticides (75) 75
adult (74) 74
research (71) 71
thiazoles - administration & dosage (66) 66
thiazoles - metabolism (66) 66
entomology (65) 65
middle aged (63) 63
mice (59) 59
piperazines - therapeutic use (56) 56
cost-benefit analysis (55) 55
treatment outcome (55) 55
toxicity (54) 54
aged (52) 52
microbiology (52) 52
dose-response relationship, drug (51) 51
rats (48) 48
thiazoles - toxicity (48) 48
thiazoles - analysis (46) 46
antipsychotic agents - therapeutic use (42) 42
chemistry, applied (42) 42
medicine, general & internal (42) 42
thiazolidinediones (42) 42
biotechnology & applied microbiology (41) 41
cell survival - drug effects (41) 41
pesticides (41) 41
chemistry, medicinal (40) 40
drug therapy (39) 39
research article (39) 39
benzothiazoles (38) 38
united states (38) 38
cell line, tumor (36) 36
schizophrenia - drug therapy (36) 36
usage (36) 36
care and treatment (35) 35
chemistry, organic (35) 35
dasatinib (35) 35
double-blind (34) 34
article (33) 33
derivatives (33) 33
efficacy (33) 33
molecular structure (33) 33
cancer (32) 32
coloring agents (32) 32
mass spectrometry (32) 32
thiazole (32) 32
time factors (32) 32
management (30) 30
schizophrenia (30) 30
bacteria (29) 29
cell line (29) 29
hypoglycemic agents - therapeutic use (29) 29
in-vitro (29) 29
multidisciplinary sciences (29) 29
physiological aspects (28) 28
piperazines - economics (28) 28
plant extracts - pharmacology (28) 28
antioxidants (27) 27
chromatography, high pressure liquid (27) 27
drug therapy, combination (27) 27
imatinib mesylate (27) 27
imidacloprid (27) 27
medicine (27) 27
mortality (27) 27
nitro compounds (27) 27
oxazines (27) 27
administration, oral (26) 26
clinical trials as topic (26) 26
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (26) 26
pyridines - therapeutic use (26) 26
urinary bladder, overactive - drug therapy (26) 26
cytotoxicity (25) 25
drugs (25) 25
health care sciences & services (25) 25
pyrimidines - therapeutic use (25) 25
acetanilides - therapeutic use (24) 24
biochemistry & molecular biology (24) 24
insecticides - toxicity (24) 24
nitro compounds - toxicity (24) 24
quetiapine fumarate (24) 24
apoptosis (23) 23
diabetes mellitus, type 2 - drug therapy (23) 23
environmental sciences (23) 23
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (769) 769
Spanish (4) 4
Dutch (3) 3
Chinese (2) 2
French (2) 2
German (2) 2
Hungarian (2) 2
Japanese (2) 2
Russian (2) 2
Arabic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Infectious Diseases, ISSN 1058-4838, 2014, Volume 58, Issue 7, pp. 928 - 936
Background. Several combinations of 2 or 3 direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment-naive patients. DAAs... 
sofosbuvir | faldaprevir | ribavirin | simeprevir | daclatasvir | INFECTIOUS DISEASES | MICROBIOLOGY | IMMUNOLOGY | POTENT | BI 201335 | HIV | INHIBITOR | ANTIRETROVIRAL TREATMENT | Heterocyclic Compounds, 3-Ring - economics | Simeprevir | Oligopeptides - economics | Hepatitis C - drug therapy | Ribavirin - economics | Humans | Imidazoles - chemistry | Uridine Monophosphate - chemistry | Uridine Monophosphate - economics | Thiazoles - therapeutic use | Health Services Accessibility - economics | Oligopeptides - therapeutic use | Antiviral Agents - chemistry | Drug Industry - economics | Imidazoles - therapeutic use | Drug Therapy, Combination | Oligopeptides - chemistry | Thiazoles - economics | Uridine Monophosphate - therapeutic use | Sulfonamides - chemistry | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Ribavirin - chemistry | Anti-HIV Agents - chemistry | Sulfonamides - therapeutic use | Imidazoles - economics | Heterocyclic Compounds, 3-Ring - chemistry | Heterocyclic Compounds, 3-Ring - therapeutic use | Sulfonamides - economics | Uridine Monophosphate - analogs & derivatives | Thiazoles - chemistry | Developing Countries | Antiviral Agents - economics | Hepacivirus | Sofosbuvir | Economic aspects | Antiviral agents | Production management | Care and treatment | Hepatitis C | Hepatitis | Antiviral drugs | Medical treatment | Developing countries--LDCs | and Commentaries
Journal Article
Journal Article
Journal Article
Thrombosis Research, ISSN 0049-3848, 02/2017, Volume 150, pp. 123 - 130
The comparative cost-effectiveness of all oral anticoagulants approved up to date has not been evaluated from the US perspective. The objective of this study... 
Anticoagulation | Cost-effectiveness | Atrial fibrillation | Non-vitamin K antagonist oral anticoagulants | CARDIOVASCULAR EVENTS | EDOXABAN | APIXABAN | MAJOR HEMORRHAGE | PROPHYLAXIS | DABIGATRAN | WARFARIN | MOLECULAR-WEIGHT HEPARIN | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | ISCHEMIC-STROKE | SYSTEMIC EMBOLISM | Dabigatran - adverse effects | Markov Chains | Pyrazoles - therapeutic use | Humans | Anticoagulants - economics | Warfarin - adverse effects | Warfarin - economics | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Thiazoles - adverse effects | Warfarin - therapeutic use | Atrial Fibrillation - economics | Pyridines - adverse effects | Rivaroxaban - adverse effects | Aged, 80 and over | Pyridones - economics | Rivaroxaban - therapeutic use | Pyrazoles - adverse effects | Pyridines - therapeutic use | Rivaroxaban - economics | Thiazoles - economics | Quality-Adjusted Life Years | Stroke - prevention & control | Atrial Fibrillation - complications | Stroke - economics | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Pyrazoles - economics | Dabigatran - economics | Cost-Benefit Analysis | Pyridines - economics | Aged | Pyridones - therapeutic use | Hemorrhage - chemically induced | Pyridones - adverse effects | Prevention | Stroke (Disease) | Warfarin | Diet therapy | Anticoagulants (Medicine) | Medical care, Cost of
Journal Article
Journal Article
Current Medical Research & Opinion, ISSN 0300-7995, 1/2014, Volume 30, Issue 1, pp. 89 - 97
Abstract Objectives: Review of the available data on the currently available single-tablet regimens (STRs), from the analysis of efficacy and safety to the key... 
Fixed-dose | STR | HIV | Single-tablet | COST-EFFECTIVENESS ANALYSIS | ONE-PILL | MEDICINE, RESEARCH & EXPERIMENTAL | INFECTION ANALYSIS | TENOFOVIR DF | INITIAL TREATMENT | ANTIRETROVIRAL THERAPY | EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE | MEDICINE, GENERAL & INTERNAL | DOUBLE-BLIND | FORMULATED ELVITEGRAVIR | FIXED-DOSE COMBINATION | Anti-HIV Agents - economics | Nitriles - economics | Quinolones - economics | Rilpivirine | Humans | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Reverse Transcriptase Inhibitors - administration & dosage | Adenine - economics | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - therapeutic use | Quinolones - therapeutic use | Anti-HIV Agents - therapeutic use | Reverse Transcriptase Inhibitors - therapeutic use | Thiazoles - economics | Emtricitabine | Organophosphonates - economics | Adenine - analogs & derivatives | Tablets - therapeutic use | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Deoxycytidine - administration & dosage | Reverse Transcriptase Inhibitors - economics | Carbamates - economics | Deoxycytidine - economics | Pyrimidines - economics | Adenine - administration & dosage | Organophosphonates - administration & dosage | Quinolones - administration & dosage | Pyrimidines - therapeutic use | HIV Infections - drug therapy | Carbamates - therapeutic use | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Nitriles - therapeutic use
Journal Article
Europace, ISSN 1099-5129, 10/2016, Volume 18, Issue 10, pp. 1507 - 1513
Journal Article
PSYCHIATRIC SERVICES, ISSN 1075-2730, 05/2008, Volume 59, Issue 5, pp. 500 - 506
The authors provide an overview of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) sponsored by the National Institute of Mental... 
METAANALYSIS | NEW-GENERATION ANTIPSYCHOTICS | PSYCHIATRY | QUETIAPINE | RISPERIDONE | RANDOMIZED CONTROLLED-TRIAL | INTERVENTION EFFECTIVENESS CATIE | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | 2ND-GENERATION ANTIPSYCHOTICS | HEALTH POLICY & SERVICES | CONVENTIONAL ANTIPSYCHOTICS | OLANZAPINE | CLINICAL ANTIPSYCHOTIC TRIALS | Dibenzothiazepines - economics | Antipsychotic Agents - adverse effects | Humans | Middle Aged | Psychology | Piperazines - economics | Male | Thiazoles - therapeutic use | Thiazoles - adverse effects | Risperidone - economics | Dibenzothiazepines - therapeutic use | Risperidone - therapeutic use | Antipsychotic Agents - therapeutic use | Dibenzothiazepines - adverse effects | Risperidone - adverse effects | Adult | Female | Benzodiazepines - economics | Schizophrenia - economics | Antipsychotic Agents - economics | Thiazoles - economics | Dyskinesia, Drug-Induced - etiology | Dyskinesia, Drug-Induced - epidemiology | Double-Blind Method | Drug Administration Schedule | Perphenazine - therapeutic use | Quetiapine Fumarate | Piperazines - therapeutic use | Piperazines - adverse effects | Cost-Benefit Analysis | Adolescent | Perphenazine - economics | Aged | Benzodiazepines - adverse effects | Perphenazine - adverse effects | Schizophrenia - drug therapy | Benzodiazepines - therapeutic use | Index Medicus
Journal Article
Journal Article
Journal Article
Journal Article
American journal of cardiovascular drugs : drugs, devices, and other interventions, 08/2018, Volume 18, Issue 4, p. 317
Several studies have compared the cost effectiveness of non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin using results from clinical trials... 
Dabigatran - adverse effects | Markov Chains | Dabigatran - administration & dosage | Anticoagulants - administration & dosage | Humans | Anticoagulants - economics | Warfarin - adverse effects | Thiazoles - administration & dosage | Antithrombins - administration & dosage | Hemorrhage - prevention & control | Warfarin - economics | Risk Adjustment - methods | Warfarin - administration & dosage | Rivaroxaban - administration & dosage | Thiazoles - adverse effects | Factor Xa Inhibitors - administration & dosage | Dose-Response Relationship, Drug | Pyridones - administration & dosage | Pyridines - adverse effects | Factor Xa Inhibitors - economics | Rivaroxaban - adverse effects | Pyridones - economics | Pyrazoles - adverse effects | Rivaroxaban - economics | Thiazoles - economics | Quality-Adjusted Life Years | Stroke - prevention & control | Pyridines - administration & dosage | Atrial Fibrillation - drug therapy | Atrial Fibrillation - complications | Anticoagulants - adverse effects | Pyrazoles - economics | Dabigatran - economics | Pyrazoles - administration & dosage | Stroke - etiology | Antithrombins - economics | Antithrombins - adverse effects | Cost-Benefit Analysis | Factor Xa Inhibitors - adverse effects | Pyridines - economics | Hemorrhage - chemically induced | Pyridones - adverse effects | Therapeutic Equivalency
Journal Article
Journal of Medical Economics, ISSN 1369-6998, 7/2013, Volume 16, Issue 7, pp. 951 - 961
Journal Article
Value in Health, ISSN 1098-3015, 2015, Volume 18, Issue 6, pp. 783 - 790
Journal Article